Short communication: Comparison of susceptibilites of Escherichia coli urinary tract isolates against fosfomycin tromethamine and different antibiotics;Kisa bi̇ldi̇ri̇: Üri̇ner si̇stem Escherichia coli i̇zolatlarinin fosfomi̇si̇n trometamol ve çeşi̇ tli̇ anti̇bi̇yoti̇klere karşi duyarliliklarinin karşilaştirilmasi

Mikrobiyoloji Bulteni

Volumn 41, Issue 1, 2007, Pages 115-119

  Aykut Arca, Ebru ^a   Karabiber, Nihal ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

Antibiotic susceptibility; Escherichia coli; Fosfomycin susceptibility; Urinary tract infections

Indexed keywords

ANTIINFECTIVE AGENT; DRUG DERIVATIVE; FOSFOMYCIN; FOSFOMYCIN TROMETHAMINE; TROMETAMOL; UNCLASSIFIED DRUG;

ARTICLE; BACTERIURIA; COMPARATIVE STUDY; DRUG EFFECT; ENTEROBACTER INFECTION; ESCHERICHIA COLI; HUMAN; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; TURKEY (REPUBLIC); URINARY TRACT;

ANTI-BACTERIAL AGENTS; BACTERIURIA; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FOSFOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; TROMETHAMINE; TURKEY; URINARY TRACT;

EID: 34748864285     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Nicolle LE. Urinary tract infection: traditional pharmacologic therapies. Am J Med 2002; 113 (Suppl 1A): 35S-44S.
2. Ungheri D, Albini E, Belluco G. In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol. J Chemother 2002; 14: 237-40.
3. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents 2003; 22 (Suppl 2): 53-9.
4. Taşbakan MI, Pullukçu H, Yamazhan T, Arda B, Ulusoy S. Toplum kökenli üriner sistem enfeksiyonlarindan soyutlanan Escherichia coli kökenlerine karşi fosfomisinin invitro etkinliǧinin diger antibiyotiklerle karşilaştirilmasi. XXXI. Türk Mikrobiyoloji Kongresi. 19-23 Eylül 2004, Kuşadasi, Aydin. Kongre Kitabi s: 404, P447.
5. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 2000, 10th Informational Supplement M100-S10. NCCLS, Wayne, PA.
6. Daza R, Gutierrez J, Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents 2001; 18: 211-5.
7. Fuchs PC, Barry AL, Brown SD. Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J Antimicrob Chemother 1999; 43: 137-40.
8. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 2003; 47: 2850-8.
9. Tezer Y, Yeşilkaya A, Memikoǧlu KO, Azap A, Tekeli E. İdrarda izole edilen kinolon dirençli Escherichia coli suşlarinda fosfomisin trometamol ve çeşitli antimikrobiyal duyarliliklarinin karşilaştirilmasi. XXXI. Türk Mikrobiyoloji Kongresi. 19-23 Eylül 2004, Kuşadasi, Aydin. Kongre Kitabi s: 273, P018.
10. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007; 29: 62-5.
11. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997; 53: 637-56.
12. Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents 2003; 22 (Suppl 2): 79-83.